Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$494K Sell
6,040
-11
-0.2% -$836 0.12% 100
2022
Q3
$370K Buy
6,051
+1
+0% +$73 0.08% 105
2022
Q2
$423K Buy
6,050
+17
+0.3% +$1.24K 0.09% 96
2022
Q1
$499K Buy
6,033
+28
+0.5% +$2.27K 0.08% 103
2021
Q4
$524K Buy
6,005
+7
+0.1% +$657 0.08% 103
2021
Q3
$523K Buy
5,998
+8
+0.1% +$707 0.08% 96
2021
Q2
$466K Buy
5,990
+9
+0.2% +$705 0.07% 105
2021
Q1
$420K Buy
5,981
+8
+0.1% +$518 0.07% 103
2020
Q4
$386K Hold
5,973
0.07% 109
2020
Q3
$339K Buy
5,973
+9
+0.2% +$511 0.06% 109
2020
Q2
$329K Buy
5,964
+9
+0.2% +$477 0.07% 106
2020
Q1
$319K Buy
5,955
+18
+0.3% +$929 0.08% 104
2019
Q4
$325K Buy
5,937
+9
+0.2% +$495 0.09% 104
2019
Q3
$321K Buy
5,928
+1,845
+45% +$102K 0.11% 91
2019
Q2
$228K Sell
4,083
-3,499
-46% -$189K 0.1% 98
2019
Q1
$415K Buy
7,582
+16
+0.2% +$815 0.18% 79
2018
Q4
$394K Sell
7,566
-1,402
-16% -$67.2K 0.2% 77
2018
Q3
$444K Buy
8,968
+28
+0.3% +$1.36K 0.25% 73
2018
Q2
$394K Buy
8,940
+3,000
+51% +$138K 0.23% 81
2018
Q1
$272K Hold
5,940
0.18% 89
2017
Q4
$281K Buy
+5,940
New +$291K 0.18% 92

Other funds holding ORCL

Burleson & Co's ORCL Position: Q4 2022 in Review

Burleson & Co reduced its Oracle (ORCL) stake by 0.18% in Q4 2022, selling an estimated $836 and leaving 6,040 shares worth $494K. The position accounts for 0.12% of the portfolio, ranked #100.

Burleson & Co first reported a position in ORCL in Q4 2017 and has held it in 21 quarters since. The position peaked at $524K in Q4 2021. 2,300 funds tracked by Wall St. Rank hold ORCL as of Q4 2022.

  • Burleson & Co held 6,040 shares of Oracle worth $494K as of Q4 2022.
  • Burleson & Co sold 11 Oracle shares in Q4 2022, an estimated $836.
  • Oracle made up 0.12% of Burleson & Co's portfolio in Q4 2022, its #100 holding.
  • Burleson & Co first reported a position in Oracle in Q4 2017 and has held it in 21 quarters since.
  • Burleson & Co's Oracle position peaked at $524K in Q4 2021.
  • 2,300 funds tracked by Wall St. Rank held Oracle as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.